DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response.
Esra OktayFarhang AlemKeziah HernandezMichael GirgisChristopher GreenDivita MathurIgor L MedintzAarthi NarayananRémi VenezianoPublished in: Communications biology (2023)
Effective and safe vaccines are invaluable tools in the arsenal to fight infectious diseases. The rapid spreading of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the coronavirus disease 2019 pandemic has highlighted the need to develop methods for rapid and efficient vaccine development. DNA origami nanoparticles (DNA-NPs) presenting multiple antigens in prescribed nanoscale patterns have recently emerged as a safe, efficient, and easily scalable alternative for rational design of vaccines. Here, we are leveraging the unique properties of these DNA-NPs and demonstrate that precisely patterning ten copies of a reconstituted trimer of the receptor binding domain (RBD) of SARS-CoV-2 along with CpG adjuvants on the DNA-NPs is able to elicit a robust protective immunity against SARS-CoV-2 in a mouse model. Our results demonstrate the potential of our DNA-NP-based approach for developing safe and effective nanovaccines against infectious diseases with prolonged antibody response and effective protection in the context of a viral challenge.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- circulating tumor
- coronavirus disease
- infectious diseases
- cell free
- single molecule
- immune response
- mouse model
- nucleic acid
- circulating tumor cells
- dna methylation
- toll like receptor
- risk assessment
- case report
- atomic force microscopy
- climate change
- transcription factor
- high resolution
- loop mediated isothermal amplification
- human health